Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,767 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+ - NCT07360314RecruitingPhase 1
A new drug targeting Ly6E for advanced solid tumors
This trial tests a new drug called M7437 that targets a protein (Ly6E) found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07346846RecruitingPhase 1
Testing BGM-2121 for advanced solid tumors
This study tests an experimental drug called BGM-2121 for people with advanced solid tumors that have not responded to or stopped responding to standard treatments. The goal is to see if the drug is safe and if it can shrink tumors.
TainanAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT07348653RecruitingPhase 1
Study of MG2512 for advanced solid tumor patients
This trial tests a new drug called MG2512 for people with advanced solid tumors that have not responded to standard treatments or who cannot take standard therapy. The study aims to understand if MG2512 is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06443489RecruitingPhase 1
SHR-4849 for advanced solid tumors
This trial tests a new drug called SHR-4849 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have limited choices.
Jilin City, ChangchunAges 18–75 - NCT07328217RecruitingPhase 1/Phase 2
Study of GW5282 for advanced solid tumors
This trial tests a new oral drug, GW5282, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07326488RecruitingPhase 1/Phase 2
Study of MHB009C for advanced solid tumors
This trial tests a new drug called MHB009C for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07321574RecruitingPhase 2
Testing ABP1011T for advanced solid tumors
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Luoyang, HenanAges 18–75 - NCT05142423RecruitingPhase 1/Phase 2
First study of AK109 plus AK104 for advanced solid cancers
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT07310134RecruitingPhase 1
Study of ZX-8177 for advanced solid tumors
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
ShanghaiAges 18 years+ - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07304128RecruitingPhase 1
PLB-002 for advanced solid tumors study
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07300943RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug (an ATR inhibitor) for people with advanced solid tumors that have not responded to or are not suitable for standard treatments. It aims to see if the drug is safe and effective, and it may be an option if you have good heart function and are feeling well enough to participate.
Boston, MassachusettsAges 18 years+ - NCT07299747RecruitingPhase 1/Phase 2
Study of VBC103 for advanced solid tumors
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07292402RecruitingPhase 1
Study of JSKN022 for advanced solid tumors
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07285395RecruitingPhase 1
Study of AT1019 with radiation and immunotherapy for advanced solid tumors
This trial tests a new drug called AT1019 given together with targeted radiation (SBRT) and an immunotherapy drug for people with advanced solid tumors that are already being treated with immunotherapy. It aims to see if this combination can shrink or control tumors better.
Xuzhou, JiangsuAges 18 years+ - NCT05970016RecruitingPhase 1/Phase 2
Study for advanced solid cancers with a DNA repair target
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Beijing, Beijing MunicipalityAges 18–70 - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT07259889RecruitingPhase 1
CEL001 injection safety study for advanced solid tumors
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
BeijingAges 18 years+ - NCT07266285RecruitingPhase 1
Testing BTM-3566 for advanced solid tumors
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,767 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.